A Randomized Phase II Trial of Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma
First-line NIVO/IPI in patients with advanced Merkel cell carcinoma demonstrated an exceptionally high ORR with durable responses and an expected safety profile.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy
- Repurposed pinworm medication shows ‘promise’ as treatment for Merkel cell carcinoma
- Merkel Cell Carcinoma: Epidemiology, Target, and Therapy
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
- Avelumab in patients with chemotherapy‑refractory metastatic Merkel cell carcinoma: a multicentre, single‑group, open‑label, phase 2 trial